Patents & Licensing
Gilead’s early, systematic approach towards non-exclusive voluntary licensing helps efficient scale up and affordable supply of patented medicines in low- and middle-income countries.
Gilead and Bristol-Myers Squibb take the first moves, from companies in scope of the Access to Medicine Index 2016, outside non-exclusive voluntary licensing in HIV/AIDS.
AstraZeneca, GSK and Merck KGaA publicly disclose their patent filing and enforcement policy, and disclose or commit to disclose their patent status and licensing approach to support third party manufacture and/or supply of patented products.
GSK boosts the geographic scope of the dolutegravir (Tivicay®) licence beyond the stated territory by more than 30 middle-income countries.